SART3

Across TCGA pan-cancer cohorts, SART3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SART3 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SART3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SART3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where SART3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.979	0.902	.010	20	view →
CCRCC	OS	Median	All	0.909	1.000	.019	17	view →
PDAC	OS	Median	II,III,IV	0.637	0.366	.004	12	view →
LUAD	DFS	Tertile	II,III,IV	0.866	0.391	.049	2	view →
HNSC	OS	Median	All	0.812	0.897	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SART3–LSCC (DFS)

Open the LSCC breakdown →